Author: Jane Edwards|| Date Published: December 8, 2020
Palantir Technologies (NYSE: PLTR) has received a potential three-year, $44.4M contract from the Food and Drug Administration to provide software that could be used to analyze data associated with drug reviews and inspections, Bloomberg reported Monday.
The FDA’s Center for Drug Evaluation and Research and the Oncology Center of Excellence will use Palantir software to facilitate the approval process for potential COVID-19 treatments and other drugs and track the safety of hand sanitizers and other items.
The report said government work now accounts for more than half of Palantir’s total revenue. The company is working on software for a new system – Tiberius – that could help federal health officials track the production, distribution and administration of COVID-19 vaccines.
Palantir went public through a direct listing in September and received a valuation of approximately $21B during its trading debut.
Brian Meyer, federal field chief technology officer at Axonius Federal, said cybersecurity asset management could help government agencies make dozens…
“Technology transformation company Red River has acquired Invictus International Consulting to expand its cybersecurity and enterprise modernization capabilities to support…
Synergy ECP, a software engineering, cybersecurity and systems engineering services provider, has acquired NetServices, a company offering secure, mission-focused technology services. The…
Precision Aerospace & Defense Group and FACT II Acquisition, a special purpose acquisition company, have signed a definitive business combination agreement to…
LMI has announced the acquisition of intellectual property and advanced capabilities to broaden its in-transit visibility and asset tracking services for…
